2024-09-03 - Analysis Report
## GILD Stock Analysis

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that researches, develops, and commercializes medicines for the treatment of life-threatening diseases.

**1. Performance Comparison:**

* **Cumulative Return:** GILD (14.51%) significantly lags behind the S&P 500 (VOO, 89.66%).
* **Relative Divergence:** GILD is currently 75.15% lower than the S&P 500, placing it at the 15.83% percentile in terms of historical relative performance. 

**2. Recent Price Movements:**

* **Closing Price:** $79.0
* **5-day Moving Average:** $78.19
* **20-day Moving Average:** $75.47
* **60-day Moving Average:** $71.78

The price is currently above all three moving averages, suggesting a potential upward trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 87.42 - High RSI indicates an overbought condition.
* **PPO (Percentage Price Oscillator):** 0.4 - Positive PPO suggests potential upward momentum.
* **Delta_Previous_Relative_Divergence:** -5.9 -  Negative value suggests a recent decline in relative performance.
* **Expected_Return:** 21.27% -  This represents the maximum 5-year expected return on investment.

The indicators suggest mixed signals, with strong momentum but potential overvaluation and recent weakening relative performance.

**4. Recent Earnings and Outlook:**

| Date        | EPS    | Revenue          |
|-------------|--------|-------------------|
| 2024-08-08 | 1.29  | 6.95 B$         |
| 2024-05-08 | -3.34 | 6.69 B$         |
| 2023-11-07 | 1.75  | 7.05 B$         |
| 2023-08-04 | 0.84  | 6.60 B$         |
| 2024-08-08 | 0.84  | 6.60 B$         |

The latest earnings report (2024-08-08) showed a positive EPS of 1.29 and revenue of 6.95B$, exceeding analysts' expectations. However, earnings have been volatile in recent quarters. It is important to monitor upcoming earnings releases and analyst forecasts for future performance insights.

**5. Overall Analysis:**

GILD has significantly underperformed the S&P 500 in terms of cumulative return and has experienced a recent decline in relative performance. Despite strong momentum indicated by technical indicators, the high RSI suggests potential overvaluation. The latest earnings beat and positive outlook offer some optimism, but the recent volatility in earnings necessitates close monitoring.

**6. Conclusion:**

GILD is a company with a strong position in the biopharmaceutical industry. However, the stock's current performance, relative to the market, presents a mixed outlook. While the stock shows signs of potential for growth, the overbought conditions and volatile earnings require a cautious approach. Investors should carefully consider all factors before making any investment decisions and monitor the company's future performance closely. 
